CTGF expression in mesangial cells: Involvement of SMADS, MAP kinase, and PKC

Kidney International

Volumn 62, Issue 4, 2002, Pages 1149-1159

  Chen, Youjun ^a,b,c   Blom, Ingrid E ^a,b,c   Sa, Susan ^a,b,c   Goldschmeding, Roel ^a,b,c   Abraham, David J ^a,b,c   Leask, Andrew ^a,b,c  

^a FIBROGEN INC   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Connective tissue growth factor; Gene regulation; Kidney fibrosis; Mitogen activated protein kinase; Protein kinase C; SMADs; Wound healing

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RAS PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVITY; GENE EXPRESSION; MESANGIUM CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0036378148     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00567.x     Document Type: Article

References (60)

1. BORDER WA, NOBLE NA: Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 54:1390-1391, 1998
2. CHEN S, HONG SW, IGLESIAS-DE LA CRUZ MC, et al: The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail 23:471-481, 2001
3. LEHMANN R, SCHLEICHER ED: Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135-144, 2000
4. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
5. MCCARTNEY-FRANCIS NL, FRAZIER-JESSEN M, WAHL SM: TGFbeta: A balancing act. Int Rev Immunol 16:553-580, 1998
6. BLOBE GC, SCHIEMANN WP, LODISH HF: Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358, 2000
7. HOLMES A, ABRAHAM DJ, SA S, et al: CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276:10594-10601, 2001
8. MOUSSAD EEA, BRIGSTOCK DA: Connective tissue growth factor: What's in a name? Molec Genet Metab 71:276-292, 2000
9. DENTON C, ABRAHAM DJ: Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13:505-511, 2001
10. WAHAB NA, YEVDOKIMOVA N, WESTON BS, et al: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77-87, 2001
11. WANG S, DENICHILO M, BRUBAKER C, HIRSCHBERG R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60:96-105, 2001
12. BLOM IE, VAN DIJK AJ, WIETEN L, et al: In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 16:1139-1148, 2001
13. YOKOI H, SUGAWARA A, MUKOYAMA M, et al: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. Am J Kidney Dis 38(Suppl):S134-S138, 2001
14. ITO Y, ATEN J, BENDE RKJ, et al: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853-886, 1998
15. MURPHY M, GODSON C, CANNON S, et al: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830-5834, 1999
16. GUPTA S, CLARKSON MR, DUGGAN J, BRADY HR: Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389-1399, 2000
17. RISER BL, DENICHILO M, CORTES P, et al: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38, 2000
18. ITO Y, GOLDSCHMEDING R, BENDE R, et al: Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 12:472-484, 2001
19. LEASK A, SA S, HOLMES A, et al: The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 54:180-183, 2001
20. MORI T, KAWARE M: Shinozaki, N, et al: Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 181:153-159, 1999
21. STRATTON R, SHIWEN X, MARTINI G, et al: Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250, 2001
22. IGARASHI A, OKOCHI H, BRADHAM DM, GROTENDORST GR: Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4:637-645, 1993
23. ABRAHAM DJ, SHIWEN X, BLACK CM, et al: Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 275:15220-15225, 2000
24. RISER BL, CORTES P: Connective tissue growth factor and its regulation: A new element in diabetic glomerulosclerosis. Ren Fail 23:459-470, 2001
25. ROBERTS AB: TGF-beta signaling from receptors to the nucleus. Microbes Infect 1:1265-1273, 1999
26. WRANA JL: Crossing Smads. Sci STKE 23:RE1, 2000
27. MULDER KM: Role of ras and mapks in TGFβ signaling. Cytokine Growth Factor Rev 11:23-35, 2000
28. HARTSOUGH MT, MULDER KM: Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 270:7117-7124, 1995
29. MULDER KM, MORRIS SL: Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem 267:5029-5031, 1992
30. FREY RS, MULDER KM: Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. Cancer Lett 117:41-50, 1997
31. ENGEL ME, MCDONNELL MA, LAW BK, MOSES HL: Interdependent SMAD and JNK signaling in transforming growth factorbeta-mediated transcription. J Biol Chem 274:37413-37420, 1999
32. KUTZ SM, HORDINES J, MCKEOWN-LONGO PJ, HIGGINS PJ: TGFbeta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 114:390-414, 2001
33. PONCELET AC, DE CAESTAKER MP, SCHNAPNER HW: The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells Kidney Int 56:1354-1365, 1999
34. SOH JW, LEE EH, PRYWES R, WEINSTEIN IB: Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Mol Cell Biol 19:1313-1324, 1999
35. CHEN Y, SEGARINI P, RAOUFI F, et al: Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res 271:109-117, 2001
36. WOLTHUIS A, BOES A, RODEMANN HP, GROND J: Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 41:124-131, 1992
37. PARADIS V, DARGERE D, VIDAUD M, et al: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30:968-976, 1999
38. GROTENDORST GR, OKOCHI H, HAYASHI N: A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7:469-480, 1996
39. BLOM IE, VAN DIJK AJ, DE WEGNER RA, et al: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Mol Pathol 54:192-196, 2001
40. BLUME SW, SNYDER RC, RAY R, et al: Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88:1613-1621, 1991
41. SCHIFFER M, VON GERSDORFF G, BITZER M, et al: Smad proteins and transforming growth factor-beta signaling. Kidney Int 58(Suppl 77):S45-S52, 2000
42. PARDALI K, KURISAKI A, MOREN A, et al: Role of Smad proteins and transcription factor Sp1 in p21 (Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275:29244-29256, 2000
43. YUAN W, VARGA J: Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 276:38502-38510, 2001
44. HAYASHIDA T, PONCELET AC, HUBCHAK SC, SCHNAPER HW: TGFbeta1 activates MAP kinase in human mesangial cells: A possible role in collagen expression. Kidney Int 56:1710-1720, 1999
45. FAVATA MF, HORIUCHI KY, MANOS EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632, 1998
46. CONSTANTINOU A, HUBERMAN E: Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc Soc Exp Biol Med 208:109-115, 1995
47. MUID RE, DALE MM, DAVIS PD, et al: A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and postreceptor stimuli. FEBS Lett 293:169-172, 1991
48. GSCHWENDT M, DIETERICH S, RENNECKE J, et al: Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase C isoenzymes. FEBS Lett 392:77-80, 1996
49. MOSES S, FRANZEN A, LOVDAHL C, HULTGARDH-NILSSON A: Injury-induced osteopontin gene expression in rat arterial smooth muscle cells is dependent on mitogen-activated protein kinases ERK1/ERK2. Arch Biochem Biophys 396:133-137, 2001
50. COOK S J, RUBINFELD B, ALBERT I, MCCORMICK F: RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J 12:3475-3485, 1993
51. UEHARA Y, HORI M, TAKEUCHI T, UMEZAWA H: Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': Identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76:672-675, 1985
52. ITOH S, ITOH F, GOUMANS MJ, TEN DIJKE P: Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem 267:6954-6967, 2000
53. KANAME S, UCHIDA S, OGATA E, KUROKAWA K: Autocrine secretion of transforming growth factor-beta in cultured rat mesangial cells. Kidney Int 42:1319-1327, 1992
54. YANG X, LETTERIO J J, LECHLEIDER, RJ, et al: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18:1280-1291, 1999
55. Hu PP, SHEN X, HUANG D, et al: The MEK pathway is required form stimulation of p21 by TGFβ. J Biol Chem 274:35381-35387, 1999
56. INOKI K, HANEDA M, ISHIDA T, et al: Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-beta in mesangial cells. Kidney Int 58(Suppl 77):S76-S80, 2000
57. HANEDA M, KOYA D, KIKKAWA R: Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 38(Suppl 1):S178-S181, 2001
58. KAPOR-DREZGIC J, ZHOU X, et al: Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol 10:1193-1203, 1999
59. KUCICH U, ROSENBLOOM JC, HERRICK DJ, et al: Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. Arch Biochem Biophys 395:103-112, 2001
60. PONCELET AC, SCHNAPER HW: Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem 276:6983-6992, 2001